Please login to the form below

Not currently logged in
Email:
Password:

Lupin appoints European president

Maurice Chagnaud moves to India-based company from Teva

India-based Lupin has appointed former Teva senior VP Dr Maurice Chagnaud as president of its European business and head of inhalation strategy.

Dr Chagnaud will be based at the company's operations in Schaffhausen, Switzerland, where he will be responsible for Lupin's business strategy in Europe, including Russia and the CIS countries.

He will also be responsible for developing Lupin's core strategy for inhalation across all developed markets.

Prior to joining Lupin, Dr Chagnaud was senior VP, Central and Eastern Europe, at Israel-based Teva. He was with Teva for just under seven years, with other roles include chief commercial officer in Europe and CEO of the company's operations in France.

In addition, Dr Chagnaud's industry experience also includes time as general manager for Merck KGaA'a generics business in Italy.

20th February 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics